Francois Mercier (François Mercier)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 34

Top Venues

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

The AAPS journal

CPT: pharmacometrics & systems pharmacology

F. Hoffmann-La Roche

Université Claude Bernard Lyon 1 (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

F. Hoffmann-La Roche

Switzerland

Expert Statistician :: Biostatistics

F Hoffmann-La Roche AG

Switzerland

Pharmacometrics Section Leader :: Clinical Pharmacology

Pharsight Corp

United States

Senior Pharmacometrician :: Consulting

Novartis Institutes for BioMedical Research Inc

United States

Lead Pharmacometrician :: Modeling and Simulation

Novartis Pharma AG

Switzerland

Project Statistician

Laboratoires Fournier

France

Project Statistician :: Biostatistics

GECEM

France

Statistician :: Biometrics

Education History

Université Claude Bernard Lyon 1

France

PHD

Publications

Mélanie Guhl, Julie Bertrand, Lucie Fayette, Francois Mercier, Emmanuelle Comets
Correction: Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm. The AAPS journal 26 (4) (2024)
Danilo Alvares, Francois Mercier
Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models. Statistics in medicine (2024)
Mélanie Guhl, Julie Bertrand, Lucie Fayette, Francois Mercier, Emmanuelle Comets
Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm. The AAPS journal 26 (3) (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Danilo Alvares, Francois Mercier
Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models. Statistics in medicine 43 (17) (2024)
Mélanie Guhl, Julie Bertrand, Lucie Fayette, Francois Mercier, Emmanuelle Comets
Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm. The AAPS journal 26 (3) (2024)
Mélanie Guhl, Julie Bertrand, Lucie Fayette, Francois Mercier, Emmanuelle Comets
Correction: Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm. The AAPS journal 26 (4) (2024)
Sebastien Benzekry, Mélanie Karlsen, Célestin Bigarré, Abdessamad El Kaoutari, Bruno Gomes, Martin Stern, Ales Neubert, René Bruno, Francois Mercier, Suresh Vatakuti, Peter Curle, Candice Jamois
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers. Clinical pharmacology and therapeutics (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Mathilde Marchand, Antonio Gonçalves, Francois Mercier, Pascal Chanu, Jin Yan Jin, Jeremie Guedj, René Bruno
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Mélanie Guhl, Julie Bertrand, Lucie Fayette, Francois Mercier, Emmanuelle Comets
Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm. The AAPS journal 26 (3) (2024)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Marion Kerioui, Julie Bertrand, Solène Desmée, Christophe Le Tourneau, Francois Mercier, René Bruno, Jeremie Guedj
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter? JCO precision oncology 7 (2023)
Stefan Englert, Francois Mercier, Elizabeth A Pilling, Victoria Homer, Christina Habermehl, Stefan Zimmermann, Natalia Kan-Dobrosky
Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development. Pharmaceutical statistics (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate pharmacometric model to define the impact of second-line immuno-therapies on the survival outcome of IMpower131 study. Clinical pharmacology and therapeutics (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
Marion Kerioui, Julie Bertrand, Solène Desmée, Christophe Le Tourneau, Francois Mercier, René Bruno, Jeremie Guedj
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter? JCO precision oncology 7 (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Thomas M Braun, Francois Mercier
Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials. Statistics in medicine 41 (20) (2022)
Francois Mercier, Nassim Djebli, Mario González-Sales, Felix Jaminion, Georgina Meneses-Lorente
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology 89 (3) (2022)
Fredrik Jonsson, Christophe Schmitt, Claire Petry, Francois Mercier, Nicolas Frey, Sylvie Retout
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clinical pharmacokinetics 60 (7) (2021)
Francois Mercier, Georgina Meneses-Lorente, Paul Grimsey, Alex Phipps, Francesca Michielin
Therapeutically-induced stable disease in oncology early clinical trials. PloS one 15 (5) (2020)
Marion Kerioui, Francois Mercier, Julie Bertrand, Coralie Tardivon, René Bruno, Jérémie Guedj, Solène Desmée
Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Statistics in medicine 39 (30) (2020)
Francois Mercier, Marion Kerioui, Solène Desmée, Jeremie Guedj, Oliver Krieter, Rene Bruno
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. Journal of pharmacokinetics and pharmacodynamics 47 (6) (2020)
Alexandre Sostelly, Francois Mercier
Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab. Clinical Medicine Insights. Oncology 13 (2019)
Coralie Tardivon, Solène Desmée, Marion Kerioui, René Bruno, Benjamin Wu, France Mentré, Francois Mercier, Jeremie Guedj
Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. Clinical pharmacology and therapeutics 106 (4) (2019)
Francois Mercier, Nicola Consalvo, Nicolas Frey, Alex Phipps, Benjamin Ribba
From waterfall plots to spaghetti plots in early oncology clinical development. Pharmaceutical statistics 18 (5) (2019)
Chao Xu, Patanjali Ravva, Jun Steve Dang, Johann Laurent, Céline Adessi, Christine McIntyre, Georgina Meneses-Lorente, Francois Mercier
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel. Cancer chemotherapy and pharmacology 82 (3) (2018)

Francois Mercier (François Mercier)

Publication Activity (10 Years)

Top Topics

Top Venues